Citius Oncology Inc. (NASDAQ:CTOR) said it has signed an exclusive agreement with Uniphar to broaden access to LYMPHIR (denileukin diftitox-cxdl) across selected Western and Eastern European markets.
Under the terms of the deal, Uniphar will act as the sole distribution partner for LYMPHIR via country-specific managed access programs, where allowed under local regulations. Citius Oncology will provide finished product supply and ongoing support. The therapy is not approved for commercial sale outside the United States and will be made available strictly through managed access programs, which do not represent formal marketing authorization or a commercial launch.
The partnership marks the company’s third international distribution arrangement, following earlier agreements covering Southern Europe, the Balkans, Turkey, and the Middle East. Citius Oncology operates as a subsidiary of Citius Pharmaceuticals Inc.
“This agreement with Uniphar builds on the momentum of our international expansion efforts and reflects our commitment to partnering with experienced organizations that have deep regional expertise and proven execution capabilities,” said Leonard Mazur, Chairman and CEO of Citius Oncology.
LYMPHIR is a targeted immune therapy for patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL), indicated for Stage I-III disease after at least one prior systemic treatment. The U.S. Food and Drug Administration approved the therapy in December 2025 for adult patients with relapsed or refractory Stage I-III CTCL who have received at least one prior systemic therapy.
Uniphar, based in Dublin, Ireland, is a global healthcare services provider operating in 180 countries and employing more than 3,500 people. The company partners with over 200 multinational pharmaceutical and medical technology firms.